IRADIMED CORP (IRMD)
Health Care · Medical Devices · NASDAQ
IRADIMED CORP provides specialized MRI-compatible medical devices, specifically infusion pumps and patient monitoring systems, engineered for safe operation within magnetic resonance imaging environments.
What IRADIMED CORP does
IRADIMED CORP designs, develops, manufactures, and distributes MRI-compatible medical devices. Its primary product focus is on MRI-compatible infusion pump systems and related disposables, as well as MRI patient vital signs monitoring systems, designed for use during magnetic resonance imaging procedures.
Themes: MRI safety and compatibility, patient monitoring systems, infusion therapy equipment
Fundamentals
- Price$87.85 as of 2026-08-21 close
- Market cap$1.1B as of 2026-08-21
- 1-year return+24.6% 2025-08-21 close $70.53 → 2026-08-21 close $87.85
- P/E48.23 as of 2026-08-24
- Net margin+26.7% as of 2026-08-24
- Gross margin+75.9% as of 2026-08-24
- ROE+23.4% as of 2026-08-24
- Debt / equity0.00 as of 2026-08-24
- Revenue growth (YoY)+11.2% as of 2026-08-24
- Revenue CAGR (3y)+16.3% SEC XBRL
- Beta0.93 as of 2026-08-24
- Last reported earnings2026-05-01 SEC EDGAR Form 8-K (Item 2.02)
Dividend: yield +1.4%; at least 1 years of non-decreasing per-share dividends (SEC XBRL) — we do not hold the year before it, so the real streak may be longer.
How IRMD compares in its sector
- price-to-earnings ratiotop 25% 203 covered Health Care peers, as of 2026-08-24
- net profit margintop 10% 504 covered Health Care peers, as of 2026-08-24
- operating margintop 10% 504 covered Health Care peers, as of 2026-08-24
- gross marginmiddle range 384 covered Health Care peers, as of 2026-08-24
- return on equitytop 25% 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
- indicated dividend yieldmiddle range 71 covered Health Care peers, as of 2026-08-24
- free cash flow (absolute dollars, latest fiscal year)middle range 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Dividend coverage (FY2025)
Covered by reported results. In FY2025, IRMD's dividend was covered by reported results (earnings payout 67%, free-cash-flow payout 88%). This describes past coverage, not a forecast.
- Earnings payout67% dividends / net income
- Free-cash-flow payout88% dividends / (operating cash flow − capex)
Coverage derived from reported SEC EDGAR XBRL figures for FY2025 (dividends paid vs. net income and free cash flow, same fiscal year). This describes PAST coverage for one fiscal year — it does not predict whether a dividend will be maintained, raised, or cut, and a one-year payout ratio can be distorted by non-recurring items. Informational only — not financial advice.
How IRADIMED CORP looks technically
IRADIMED CORP (IRMD) is trading 6.8% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 7 trading days ago — a "death cross", a bearish long-term signal. A strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 29, with sellers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 40, neither overbought (above 70) nor oversold (below 30). It made a new 20-day low about 2 trading days ago. It is 18.6% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 6.8% below its 200-day average, the long-term trend line — a long-term downtrend | -6.8% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $93.32 | $93.32 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $94.26 | $94.26 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing low 7 calendar days ago — the swings before that are what the structure reading is measured on | 7 sessions |
| Wave structure | its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in the fourth leg, a pullback against that downward direction; the labelling fails if price closes above 90.83. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a completed three-part correction. | possible downward five-wave sequence, in wave 4 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 7 trading days ago — a "death cross", a bearish long-term signal | 7 sessions |
| Trend strength (14-day ADX) | a strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 29, with sellers in control | 28.6 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 40, neither overbought (above 70) nor oversold (below 30) | 40.3 |
|---|---|---|
| Position in its 14-day range | it is trading in the lower half of its 14-day range ($85.03 to $94.69) — its "stochastic" reading is 29 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 29.2 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in negative territory (momentum leaning bearish) | 29 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $107.90 | $107.90 |
|---|---|---|
| From the 52-week high | it is 18.6% below its 52-week high (its highest price of the past year) | -18.6% |
| Above the 52-week low | it is 29.5% above its 52-week low (its lowest price of the past year) | +29.5% |
| Below the 52-week high | it is 18.6% below its highest point of the past year | 18.6% |
| Since a 20-day breakout | it made a new 20-day low about 2 trading days ago | 2 sessions |
| Since a 55-day breakout | it made a new 55-day low about 2 trading days ago | 2 sessions |
| All-time high | its highest closing price on record is $107.90 (set on 2026-02-10) | $107.90 |
| Given back of the 52-week move | over the past year its closes ranged ($68.55 to $105.15), and it has given back around half of its rise from last year’s low — 47% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $81.36 to $82.53. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 47.3% |
| From the all-time high | it is 18.6% below its all-time high | -18.6% |
| Nearest price level | it is sitting right on a resistance level at $87.93 — a price it turned at four times since 2025-11-04, most recently on 2026-06-03. Since 2024-08-21 it has 10 such levels below the current price and 7 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +0.1% |
| All-time low | its lowest closing price on record is $6.26 (set on 2014-09-03) | $6.26 |
| Above the all-time low | it is 1303.4% above its all-time low | +1,303% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are wider than usual versus its own recent 6-month history (wider than about 73% of it) | 73rd percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $2.80 between its high and its low — about 3.2% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $2.80 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $84.56 and $96.31 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $84.56 – $90.44 – $96.31 |
| Typical daily range (% of price) | its price moves about 3.2% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 3.2% |
| Stretch from the 200-day average | it is trading 2.3 daily ranges below its 200-day average price (6.8% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 2.3 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.61× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | not available for this company yet | n/a |
Candlestick patterns
2
| Since a hammer | 5 sessions ago, after a stretch of decline, it sold off hard during the session and then closed back near its high — a "hammer", the long lower wick showing the drop was bought back before the close | 5 sessions ago |
|---|---|---|
| Since a bearish engulfing | 9 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 9 sessions ago |
Price gaps
2
| Gap at the open | it opened on 2026-08-21 0.2% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +0.2% |
|---|---|---|
| Gap filled | a 2.7% gap up opened on 2026-08-11 has been "filled" 8 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 8 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 9.8 percentage points (the stock lost 7.5% while the market gained 2.3%) | -9.8% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 8.8 percentage points (the stock lost 5.7% while the market gained 3.1%) | -8.8% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 26.2 percentage points (the stock lost 15.2% while the market gained 11.1%) | -26.2% |
| vs market, 12 months | over the past 12 months this stock beat the market by 4.1 percentage points (the stock gained 24.6% while the market gained 20.5%) | +4.1% |
Signal agreement
2
| Bullish technical signals | 0 of the 9 technical signals we can compute for it are currently in a bullish state — these describe past price behaviour, not a forecast | 0 of 9 |
|---|---|---|
| Bearish technical signals | 7 of the 9 technical signals we can compute for it are currently in a bearish state: a strong downtrend, with sellers in control, a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, a fresh 20-day low, MACD momentum is negative, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 7 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 2.4% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is moderate, spanning 7.6% of the share price. | -2.4% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 7% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $93.96 — a volume-weighted average of daily closes over 158 sessions, not a true tick-by-tick VWAP. | -6.5% |
|---|---|---|
| Vs the average paid since it last reported | the price is 2% below the average price paid since it last reported on 2026-07-31 (its 10-Q), so the typical buyer over that stretch is under water. That average is $89.75 — a volume-weighted average of daily closes over 16 sessions, not a true tick-by-tick VWAP. | -2.1% |
Price levels it has turned at before
IRMD last closed at $87.85 on 2026-08-21. Since 2024-08-21 it has turned at 10 prices below its last close and 7 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $87.93 | Resistance | 0.1% above the last close | turned there four times · 2025-11-04 to 2026-06-03 |
| $90.44 | Resistance | 3.0% above the last close | turned there five times · 2025-12-04 to 2026-07-31 |
| $82.92 | Support | 5.6% below the last close | turned there twice · 2025-11-14 to 2026-05-12 |
| $93.10 | Resistance | 6.0% above the last close | turned there twice · 2026-02-04 to 2026-07-23 |
| $73.97 | Support | 15.8% below the last close | turned there three times · 2025-08-13 to 2025-09-11 |
| $71.63 | Support | 18.5% below the last close | turned there twice · 2025-08-04 to 2025-10-14 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 4 of five, a pullback against that direction.
This labelling fails — stops being a possible reading at all — if it closes above $90.83.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $88.03 and $90.83 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a completed three-part correction, which fails on a close below $85.03.
This labelling was already in place when we began recording count changes on 2026-08-13, so how long it has stood is not something we can say yet.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Recent death cross (50-day crossed below 200-day) · Broke down to a new 20-day low · lagging the market · Under water since its last earnings report (below the anchored VWAP) · Trading below the Ichimoku cloud | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Mean price target$118.00 range $116.00 – $120.00
Analyst estimates, as of 2026-08-21. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for IRMD
- Consensus EPS estimate$0.545 next reporting period, as of 2026-08-21
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Significant reliance on regulatory clearances (510(k)) and ongoing FDA compliance.","Concentration risk due to reliance on a limited number of products.","Exposure to product liability claims and potential manufacturing defects."]
What changed in the latest 10-Q
AI-assisted comparison of IRMD's 10-Q filed 2026-05-01 against the prior one filed 2025-11-03.
Management's Discussion & Analysis (MD&A)
- Added:
- Reference to fiscal year ended December 31, 2025 in the 2025 Annual Report (newer filing 2026-05-01)
- Forward-looking statement language changed to 'The Company undertakes no obligation to publicly update or revise any forward-looking statement contained in this Quarterly Report, whether as a result of new information, future developments, or otherwise, except as required by applicable law' (newer filing 2026-05-01)
- Removed:
- Reference to fiscal year ended December 31, 2024 in the 2024 Annual Report (older filing 2025-11-03)
- Forward-looking statement language 'We do not intend to, and disclaim any obligation to, update or revise any forward-looking statements unless required by securities law' removed (older filing 2025-11-03)
- Operating lease right-of-use asset line item of $154,688 as of December 31, 2024 (older filing 2025-11-03)
- Current portion of operating lease liabilities of $153,264 (older filing 2025-11-03)
- Operating lease liabilities, non-current of $1,424 (older filing 2025-11-03)
- Nine months ended September 30 comparative financial data (older filing 2025-11-03)
- Six-month and nine-month cumulative stockholders' equity statements showing March 31, 2025, June 30, 2025, and September 30, 2025 balances (older filing 2025-11-03)
- Reworded:
- Balance sheet comparison dates changed from September 30, 2025 / December 31, 2024 to March 31, 2026 / December 31, 2025 (newer filing 2026-05-01)
- Income statement comparison changed from three and nine months ended September 30, 2025 / 2024 to three months ended March 31, 2026 / 2025 only (newer filing 2026-05-01)
- Stockholders' equity statement changed from nine-month period showing three quarters of activity to three-month period showing only first quarter activity (newer filing 2026-05-01)
- Cash flows statement changed from nine months ended September 30, 2025 / 2024 to three months ended March 31, 2026 / 2025 (newer filing 2026-05-01)
- Notes:
- The older filing (2025-11-03) appears to be a 10-Q for the nine-month period ending September 30, 2025, while the newer filing (2026-05-01) is a 10-Q for the three-month period ending March 31, 2026, so structural differences reflect different reporting periods rather than substantive changes to the same period
- Financial statement line items and amounts differ substantially due to different fiscal periods being reported
Risk Factors
- Added:
- Added words 'forecast,' 'outlook,' and 'guidance' to forward-looking statement identifier list (filed 2026-05-01)
- Added new risk factor on AI/ML integration: 'the risks associated with the integration of Artificial Intelligence ("AI") or Machine Learning ("ML") into our products or business, including the risk of algorithmic errors or bias, evolving and uncertain regulatory requirements applicable to AI-enabled medical devices, data privacy and security concerns arising from the use of AI or ML, and potential liability arising from AI-driven product decisions or recommendations' (filed 2026-05-01)
- Added specific language about tariffs and export controls: 'and the impact of tariffs, trade restrictions, export controls, and changes in trade policy, which could increase the cost of components and raw materials used in our products' (filed 2026-05-01)
- Removed:
- Removed 'and other risks detailed in our filings with the United States Securities and Exchange Commission (the "SEC")' catch-all language (filed 2025-11-03)
- Removed detailed closing paragraph beginning with 'These forward-looking statements involve a number of risks and uncertainties...' (filed 2025-11-03)
- Removed parenthetical about insufficient governmental funding: 'and the impact of insufficient governmental funding and related operational inefficiencies' (filed 2025-11-03)
- Removed phrase 'lead to increased volatility in the financial market and in the market in which we operate our business' and replaced with simpler language (filed 2025-11-03)
- Reworded:
- Changed 'failure to obtain and/or maintain regulatory approvals and comply with applicable regulations' to 'failure to obtain and/or maintain regulatory approvals and comply with applicable regulations' (punctuation/formatting: removed 'or clearances' in 2025-11-03, added back in 2026-05-01)
- Changed 'the failure of third parties to uphold their contractual duties or meet expected deadlines' to 'the risk that third parties may fail to uphold their contractual obligations or meet expected deadlines, which could disrupt our operations or adversely affect our financial results' (filed 2026-05-01 expands scope and consequences)
- Changed 'breaches or failures of our or our vendors' or customers' information technology systems or products, including by cyber-attack' to 'including by cyberattack' (hyphenation changed: 'cyber-attack' to 'cyberattack') (filed 2026-05-01)
- Changed reference to geopolitical risks from 'tariffs, trade disputes, international conflicts, recent or upcoming elections' to 'international conflicts, political instability and recent or upcoming elections' and separated tariffs/trade restrictions into separate clause (filed 2026-05-01)
- Changed 'the conditions in the U.S. and global economies, including the impact of increasing and/or fluctuating tax and interest rates as well as inflationary pressures on such economies' to 'increasing and/or fluctuating tax and interest rates as well as inflationary pressures on the U.S. and global economies' (simplification of phrasing) (filed 2026-05-01)
- Notes:
- Newer filing text appears truncated at the end of the geopolitical risks bullet point
- Comparison of closing language is incomplete due to truncation in newer filing
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 8 open-market sales by insiders in the last 90 days.
- Last 90 days0 buys · 8 sells ($741385) — 2 selling insiders
- Last 180 days0 buys · 54 sells ($7M) — 2 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-06-04. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about IRMD's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding IRMD as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 1,733,100
- Reported value $166,828,186
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 2 increased, 3 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
IRMD had 670,183 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
IRMD had 5.24% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 5.77 days to cover at the same settlement.
- Reported short interest (shares) 670,183
- Short interest (% of shares outstanding) 5.24%
- Prior settlement (shares) 705,832
- Reported change -5.05%
- Days to cover (reported) 5.77
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- GE HealthCare (GEHC)
- Baxter International (BAX)
- Philips (PHG)
- Becton Dickinson (BDX)
- Medtronic (MDT)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare IRMD vs…
Frequently asked questions
What does IRADIMED CORP (IRMD) do?
IRADIMED CORP designs, develops, manufactures, and distributes MRI-compatible medical devices. Its primary product focus is on MRI-compatible infusion pump systems and related disposables, as well as MRI patient vital signs monitoring systems, designed for use during magnetic resonance imaging procedures.
What sector is IRADIMED CORP (IRMD) in?
IRADIMED CORP (IRMD) is classified in the Health Care sector. Its industry is Medical Devices. It trades on NASDAQ.
Does IRMD pay a dividend?
Yes — IRADIMED CORP (IRMD) pays a dividend, with an indicated yield of about 1.42% and at least 1 years of non-decreasing per-share dividends (SEC EDGAR XBRL) — we do not hold the year before it, so the real streak may be longer (market data, as of 2026-08-24). Informational only — not financial advice.
Who are IRADIMED CORP's (IRMD) competitors?
Notable peers of IRADIMED CORP (IRMD) include GE HealthCare, Baxter International, Philips, Becton Dickinson and Medtronic. This peer set is informational only — not financial advice.
Is IRADIMED CORP (IRMD) overbought or oversold right now?
IRADIMED CORP (IRMD) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 40, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on IRMD come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.